Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

29 Jul 2026, 23:31 UTC · 2h ago

Conmed (CNMD) Reports Q2 Earnings: What Key Metrics Have to Say

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Conmed reported a substantial earnings per share (EPS) surprise of 25.46%, with actual EPS at $1.38 versus the $1.10 consensus estimate. — A significant earnings beat typically triggers a positive price correction as it indicates stronger-than-expected profitability.
+0.60
2
Conmed's revenue for the quarter ended June 2026 was $343.49 million, exceeding the Zacks Consensus Estimate by 1.85%. — The revenue beat is positive but marginal, suggesting stable growth rather than a massive acceleration.
+0.20
3
Conmed's quarterly revenue grew 0.3% year-over-year compared to the same period last year. — Flat to very low year-over-year revenue growth may be viewed as a sign of stagnation despite the earnings beat.
-0.10